Your session is about to expire
← Back to Search
CYH33 + Olaparib for Ovarian Cancer
Study Summary
This trial is testing a new combination drug to see if it is safe and effective in treating ovarian cancer that has progressed despite prior PARP inhibitor treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 220 Patients • NCT03106987Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Only certain patients are eligible for the second part of the study.You cannot take olaparib due to a medical condition or had a bad reaction to it before.You have received treatment with certain types of medication, including PARP inhibitors, PI3Kα inhibitors, AKT inhibitors, or mTOR inhibitors.You have a solid tumor that has advanced and standard treatments have not been effective, or there are no standard treatments available. You must have already received at least one type of treatment for your tumor.
- Group 1: CYH33 in Combination with Olaparib
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has CYH33 been studied previously in a research setting?
"Currently, CYH33 is the subject of 188 active clinical trials with 27 studies in their final phase. These medical research sites are primarily located in Houston, Texas but can also be found at 9250 other locations across the world."
What medical conditions have been effectively treated with the drug CYH33?
"CYH33 is most commonly prescribed to address advance directives, but it may also be effective in treating malignant neoplasm of ovary, primary peritoneal cancer and various types of somatic hallucinations."
Is this an unprecedented attempt to treat the condition?
"Since 2005, AstraZeneca has bankrolled research on the drug CYH33. After a trial involving 98 participants in its inaugural year of study, this compound was approved for Phase 1 clinical trials. Currently there are 188 active studies located across 1468 cities and 59 countries."
Is the enrollment for this medical trial still open?
"According to the information found on clinicaltrials.gov, this trial is recruiting patients at present. The experiment was initially advertised on September 28th 2020 and had its most recent update released October 10th 2022."
What risks do individuals run when using CYH33?
"CYH33's safety rating was assessed to be a 1 due to its Phase 1 status, which suggests only limited evidence for both efficacy and security."
What are the intended outcomes for this scientific experiment?
"The primary outcome to be evaluated over a period of 12 months is the Tumor Objective Response Rate (ORR). Secondary outcomes include Disease Control Rate (DCR), Progression Free Survival, pharmacokinetic measures Vz/F and Cmax."
Share this study with friends
Copy Link
Messenger